Sugi Predict

Sugi Predict / Compounds / SCHEMBL20759

SCHEMBL20759

SCHEMBL20759

CC1(C)OB(c2cnn(CCO)c2)OC1(C)C

nearest known ligand 0.64

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.64
▸ LPL P06858 7/20 0.36
▸ LIPG Q9Y5X9 7/20 0.36
▸ KIT P10721 1/20 0.35
▸ PDK2 Q15119 7/20 0.35
▸ F11 P03951 1/20 0.35
▸ PDK1 Q15118 1/20 0.34
▸ PDK3 Q15120 1/20 0.34
▸ JAK2 O60674 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ TYK2 P29597 1/20 0.33
▸ JAK3 P52333 1/20 0.33
▸ DGAT1 O75907 1/20 0.33
▸ IRAK4 Q9NWZ3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1854359 0.91 FFAR1 (0.61) FFAR1LPLLIPGPDK2F11
SCHEMBL9281960 0.89 FFAR1 (0.59) FFAR1LPLLIPGPDK2F11
Boric Acid SCHEMBL25234240 0.89 FFAR1 (0.64) FFAR1LPLLIPGKITPDK2
SCHEMBL25293264 0.88 FFAR1 (0.58) FFAR1LPLLIPGPDK2F11
SCHEMBL25297920 0.88 FFAR1 (0.58) FFAR1LPLLIPGPDK2F11
SCHEMBL2640943 0.88 FFAR1 (0.52) FFAR1KITPDK2DGAT1
SCHEMBL29582665 0.88 FFAR1 (0.61) FFAR1LPLLIPGF11DGAT1
SCHEMBL22443200 0.87 FFAR1 (0.50) FFAR1KITPDK2PDK1PDK3
SCHEMBL27031982 0.86 FFAR1 (0.56) FFAR1LPLLIPGF11JAK3
SCHEMBL1331340 0.85 FFAR1 (0.61) FFAR1LPLLIPGF11IRAK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 501 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015157360-A1 PROCESSES TO MAKE PROTEIN KINASE INHIBITORS ABBVIE INC. (US) 2015-10-15 — — WO claimed
EP-4747250-A1 KINASE INHIBITORS The United States Of America, As Represented By The Secretary, Department of Health and Human Services (US) 2026-05-27 — — EP disclosed
US-20260138986-A1 PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES BLUEPRINT MEDICINES CORP (US) 2026-05-21 — — US disclosed
US-12630563-B2 Macrocyclic RIP2-kinase inhibitors ONCODESIGN S.A. (FR) 2026-05-19 — — US disclosed
US-20260125396-A1 MACROCYCLIC RIP2-KINASE INHIBITORS ONCODESIGN S.A. (FR) 2026-05-07 — — US disclosed
EP-4719382-A1 INHIBITORS OF TYPE 1 METHIONYL-TRNA SYNTHETASE AND METHODS OF USING THEM University of Washington (US) 2026-04-08 — — EP disclosed
EP-4713095-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING DISORDERS Chengdu Anticancer Bioscience, Ltd. (CN) 2026-03-25 — — EP disclosed
EP-4103559-B1 HETEROCYCLIC PAD4 INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2026-03-04 — — EP disclosed
US-20260049080-A1 WILD TYPE KIT INHIBITORS BLUEPRINT MEDICINES CORP (US) 2026-02-19 — — US disclosed
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors INCYTE CORPORATION (US) 2026-02-17 — — US disclosed
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors UCB PHARMA S.A. (BE) 2010-03-18 — — US disclosed
US-20100063054-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-11 — — US disclosed
US-20100063054-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-03-11 — — US disclosed
US-20100063031-A1 KINASE INHIBITOR COMPOUNDS XCOVERY, INC. (US) 2010-03-11 — — US disclosed
WO-2010019899-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — WO disclosed
WO-2010019899-A1 cMET INHIBITORS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-02-18 — — WO disclosed
US-7601725-B2 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2009-10-13 — — US disclosed
US-7601725-B2 Thienopyrimidines useful as Aurora kinase inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2009-10-13 — — US disclosed
WO-2009071895-A1 FUSED THIAZOLE AND THIOPHENE DERIVATIVES AS KINASE INHIBITORS UCB PHARMA S.A. (BE) 2009-06-11 — — WO disclosed
WO-2008088881-A1 KINASE INHIBITOR COMPOUNDS XCOVERY, INC. (US) 2008-07-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049080-A1 WILD TYPE KIT INHIBITORS KIT, CSNK1A1, CSNK1A1L FFAR1 1407/4885LPL 4316/4885LIPG 3293/4885
US-20100069361-A1 Fused Thiazole Derivatives as Kinase Inhibitors JAK1, MTOR, MOK FFAR1 1621/4885LPL 2252/4885LIPG 717/4885
US-20100063054-A1 cMET INHIBITORS CEPT1, LCAT, GNMT FFAR1 4031/4885LPL 1677/4885LIPG 429/4885
US-20100063031-A1 KINASE INHIBITOR COMPOUNDS MAP4K2, MAP3K5, MAP3K15 FFAR1 4647/4885LPL 4180/4885LIPG 3571/4885
US-20260125396-A1 MACROCYCLIC RIP2-KINASE INHIBITORS RIPK1, RIPK2, RIPK4 FFAR1 273/4885LPL 1879/4885LIPG 627/4885
US-12630563-B2 Macrocyclic RIP2-kinase inhibitors RIPK1, RIPK2, RIPK3 FFAR1 1208/4885LPL 3153/4885LIPG 2095/4885
US-12552804-B2 Tricyclic heterocycles as FGFR inhibitors FGFR3, FGFR1, FGFR2 FFAR1 1016/4885LPL 2108/4885LIPG 3033/4885
US-20260138986-A1 PYRROLOTRIAZINE DERIVATIVES FOR TREATING KIT- AND PDGFRA-MEDIATED DISEASES KIT, PDGFRA, PDGFRB FFAR1 766/4885LPL 3216/4885LIPG 1091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.